Literature DB >> 2064953

Primary thrombocythaemia: diagnosis and management.

T C Pearson1.   

Abstract

Since PT is more likely than reactive thrombocytosis to be complicated by thromboembolic manifestations, the differential diagnosis is important. A combination of positive clinical and laboratory criteria probably represents the most useful diagnostic method at present, although a molecular biological approach may prove to be of value in females in the future. Treatment to suppress the megakaryocytic proliferation is suggested in all patients, since even young patients are not immune to major complications, and treatment may possibly delay long-term myelofibrotic transition. Acute haemorrhage should be treated by platelet transfusions, with or without platelet apheresis and with rapid control of the count by hydroxyurea. Vascular occlusive lesions should be treated with aspirin, with or without platelet apheresis and with hydroxyurea. Busulphan is suggested as the drug of choice for long-term therapy in patients over 40 years of age while hydroxyurea is proposed below this age. The place of interferon-alpha therapy has not yet been established but may have a particular role in women of child-bearing age.

Entities:  

Mesh:

Year:  1991        PMID: 2064953     DOI: 10.1111/j.1365-2141.1991.tb04408.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

Review 1.  Primary thrombocythemia: diagnosis, clinical manifestations and management.

Authors:  P J van Genderen; J J Michiels
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

Review 2.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  MCNU in the treatment of essential thrombocythemia--a pilot study.

Authors:  H Murakami; J Tamura; M Sawamura
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.